The dysmenorrhea treatment market size was valued at USD 3.78 billion in 2023 and is projected to grow from USD 4.08 Billion in 2024 to USD 7.69 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.21% during the forecast period (2024 - 2032). The rise in disposable income, growing awareness about menstrual health, and increased spending on healthcare are expected to drive the market growth of the dysmenorrhea treatment. The increasing number of partnerships, collaborations, and mergers and acquisitions among market players is expected to create new opportunities for market growth
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Myfembree (relugolix 40mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) was approved by the FDA in August 2022 for the treatment of endometriosis accompanied with moderate to severe pain within two years before menopause.
An over-the-counter drug – Naproxen Sodium Tablets USP, 220 mg was re-launched by Dr. Reddy’s Laboratories Ltd in August 2021 for use in the United States of America for minor pain including period pain.
Nua announced Cramps Comfort in December 2020 as a unique solution to period pains. Nua has unveiled an innovative self-heating patch that can provide up to eight hours of warmth to reduce menstrual discomfort.
Cora® introduced its new comfort-centric brand aesthetics, feel, and persona in 2022. It has also extended its product lineups to meet varying customer tastes.
The increasing awareness about menstrual health and the growing female population across the world are creating market opportunities for the dysmenorrhea treatment. Moreover, the rising prevalence of endometriosis, which is a leading cause of secondary dysmenorrhea, is also contributing to the market's growth. The high efficacy of NSAIDs and their FDA approval makes them a popular choice for dysmenorrhea treatment, which is expected to drive the market's growth further
Additionally, the market growth of the dysmenorrhea treatment is also supported by various government initiatives aimed at increasing awareness about menstrual health and promoting the usage of effective treatment options. For example, in April 2022, the World Health Organization (WHO) launched the "Every Women Every Child" initiative, aimed at improving the health and well-being of women, children, and adolescents ly. The initiative focuses on improving access to essential health services, including menstrual health management, and strengthening health systems.
Additionally, the growing number of pharmaceutical companies focused on the development of new and innovative products for the treatment of dysmenorrhea is expected to fuel the growth of the market CAGR. For instance, in December 2021, Pfizer Inc. received FDA approval for its new drug, "Menstrual Cramp Relief" for the treatment of dysmenorrhea.
In conclusion, the increasing prevalence of dysmenorrhea treatment and rising awareness about menstrual health, coupled with the efficacy of NSAIDs and a growing number of pharmaceutical companies focused on the development of new products, are expected to drive the growth of the dysmenorrhea treatment market revenue.
Figure 1: Dysmenorrhea treatment market around the globe
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The market segmentation of dysmenorrhea treatment, based on product type, includes primary dysmenorrhea, and secondary dysmenorrhea treatment. The primary dysmenorrhea treatment segment held the majority share in 2022 contributing to around ~65-67% in respect to the dysmenorrhea treatment market revenue. This is due to the increasing prevalence of primary dysmenorrhea and the rising awareness about the effective treatment options available. Factors such as changes in lifestyle, increased stress levels, and unhealthy diets can lead to an increased incidence of menstrual cramps and other symptoms associated with primary dysmenorrhea, further driving the segment's growth. Additionally, the availability of various FDA-approved NSAIDs for treating primary dysmenorrhea is expected to drive the growth of this segment.
The dysmenorrhea treatment market segmentation, based on type of treatment, includes pain relievers, hormonal therapy, and surgery. The pain reliever segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2023-2030. This is due to the widespread availability, low cost, and high therapeutic effect of non-steroidal anti-inflammatory drugs (NSAIDs) are driving the popularity of pain relievers and increasing their market share. NSAIDs are the most commonly used drugs for treating dysmenorrhea and are widely available in pharmacies and drug stores. Additionally, Bayer's study from September 2019 showed that a single maximum non-prescription dose of Aleve (naproxen sodium) provided more pain relief over 12 hours than acetaminophen for menstrual cramps due to primary dysmenorrhea. This is further expected to increase the adoption rate of NSAIDs, fueling the growth of the pain reliever drugs segment in the menstrual cramps treatment market.
The market of dysmenorrhea treatment data has been bifurcated by end users into hospitals & clinics and research centers. The hospitals and clinic segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032.
Figure 2: Dysmenorrhea Treatment Market, by End-User, 2024 & 2032 (USD billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North America Dysmenorrhea Treatment market accounted for USD 1.603 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. North America is expected to be a significant contributor to the market for dysmenorrhea treatment, with the US being a major contributor. This is due to the high incidence and prevalence of dysmenorrhea and increased awareness of the condition among women, with 31.31 million women in the US reporting menstrual/period pain in 2020. The launch of new products for treating dysmenorrhea and the approval of new drugs by the FDA are also driving the market's growth in North America.
Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: DYSMENORRHEA TREATMENT MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe dysmenorrhea treatment market accounts for the second-largest market share. The increasing prevalence of dysmenorrhea, along with the growing awareness and increasing number of R&D activities in Europe, is expected to drive the market growth of the dysmenorrhea treatment in the region. With a projected market share of 24% by 2022, Europe is expected to be one of the fastest-growing markets for dysmenorrhea treatment during the forecast period 2023-2030. Moreover, UK dysmenorrhea treatment held the largest market share, and the German dysmenorrhea treatment was the fastest-growing market in the region.
Asia Pacific market of dysmenorrhea treatment is expected to grow at the fastest CAGR from 2024 to 2032. The increasing awareness about menstrual health and the need for better treatment options is driving the growth of the Asia Pacific market for women's wellness technology. Additionally, the growth of healthcare infrastructure and government initiatives in the region are expected to further fuel dysmenorrhea treatment market growth. Further, the China dysmenorrhea treatment held the largest market share, and the Indian dysmenorrhea treatment was the fastest-growing market in the region.
Major market players are spending a lot of money on R&D to increase their product lines, which will help the market growth of Dysmenorrhea Treatment even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the dysmenorrhea treatment industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies adopted by manufacturers in the dysmenorrhea treatment industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, the dysmenorrhea treatment industry has provided medicine with some of the most significant benefits. The dysmenorrhea treatment market player such as Johnson & Johnson (US), GlaxoSmithKline, PLC (UK), Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany), and others are working to expand the market demand by investing in research and development activities.
Cramp Comfort is positioned as a novel solution for period pain relief and aims to offer a more natural alternative to traditional pain relief methods. With the increasing demand for natural and safe products, Nua's Cramp Comfort self-heating patches may appeal to women seeking more holistic approaches to managing menstrual discomfort. In September 2022, the release of Cramp Comfort highlights the growing market demand for innovative and effective products for menstrual cramps treatment. It highlights Nua as a promising player in the women's health industry.
Cora's new brand image and product line expansion aim to better serve the needs and preferences of women when it comes to menstrual care and overall wellness. The company aims to provide consumers with a range of options to choose from and ensure that they feel comfortable and confident during their periods. In April 2022, Cora launched their new products, such as the Comfort Fit Tampon, Got-You-Covered Liner, Peace-of-Mind Pad, and Perfect Fit Disc, which was designed to offer comfort and convenience during menstrual periods.
August 2022: FDA approval makes MYFEMBREE the first once-daily oral medication approved in the United States for the treatment of endometriosis-associated pain. MYFEMBREE is a combination of three drugs, relugolix (a GnRH receptor antagonist), estradiol (a type of estrogen), and norethindrone acetate (a type of progestin), designed to reduce the production of hormones that promote the growth of endometrial tissue. The approval of MYFEMBREE has been well-received by the medical community and is expected to provide a much-needed alternative for the treatment of endometriosis-associated pain in premenopausal women.
August 2021 Nonsteroidal anti-inflammatory drug (NSAID) used to relieve mild to moderate pain, including menstrual cramps, as well as swelling and stiffness caused by osteoarthritis and rheumatoid arthritis. The relaunch of this product expands Dr. Reddy’s Laboratories Ltd's portfolio in the United States and provides customers with a new option for treating minor pain, including menstrual cramps.
February 2020 Ovira's TENS device is a non-invasive and drug-free solution for menstrual cramps, and the company aims to provide women with a convenient and effective way to manage menstrual pain. The device is easy to use, portable and has been designed to provide relief for up to 8 hours with just one application.
North America
Europe
Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 3.78 billion |
| Market Size 2024 | USD 4.08 billion |
| Market Size 2032 | USD 7.69 billion |
| Compound Annual Growth Rate (CAGR) | 8.21% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018 & 2021 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product Type, Type of treatment, End-user, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Johnson & Johnson (US), GlaxoSmithKline PLC (UK), Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany), Focus Consumer, Healthcare LLC (US), Novartis AG (Switzerland), Pfizer Inc. (US), Reckitt Benckiser Group plc. (UK), Sanofi S.A. (France) |
| Key Market Opportunities | Emergence (NSAIDs) has been a major development in the dysmenorrhea treatment market. |
| Key Market Dynamics | Increasing awareness about menstrual health and the growing female population |
Dysmenorrhea Treatment Market Highlights:
Frequently Asked Questions (FAQ) :
The Dysmenorrhea Treatment market size was valued at USD 3.78 Billion in 2023.
The market is projected to grow at a CAGR of 8.21% during the forecast period, 2024-2032.
North America had the largest share of the market
The key players in the market are Johnson & Johnson (US), GlaxoSmithKline, PLC (UK), Hoffmann-La Roche Ltd (Switzerland), and Bayer AG (Germany).
The primary dysmenorrhea treatment category dominated the market in 2021.
Hospitals and clinics had the largest share of the market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
